Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00792623
Other study ID # 208133/178
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 8, 2003
Est. completion date September 10, 2007

Study information

Verified date April 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months post-transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date September 10, 2007
Est. primary completion date September 10, 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Screening phase:

- A male or female = 18 years of age at the time of study entry.

- Written informed consent obtained from the subject prior to study entry.

- Patients who are planned to undergo autologous peripheral stem cell/ bone marrow transplantation.

- Subjects who the investigator believes can and will comply with the requirements of the protocol

- If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for 10 months after transplantation.

Active phase:

- Patients who are confirmed to have undergone autologous peripheral stem cell/ bone marrow transplantation.

- If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for 10 months after transplantation.

Exclusion Criteria:

Screening phase:

- Pregnant or lactating female.

- Female planning to become pregnant or planning to discontinue contraceptive precautions in the 10 months post-transplantation.

- History of allergy to any component of the vaccine.

- Patients with difficult to treat disease who are likely to relapse within 6 months post-transplantation.

- Current drug and/or alcohol abuse.

Active phase:

- Use of any investigational or non-registered product (drug or vaccine) during the active phase of the study period.

- Use of immunosuppressants or other immune-modifying drugs within 14 days preceding the administration of the first dose of the study vaccine or planned use during the active phase of the study period.

- Use of rituximab (MabThera) more than 60 days after transplant.

- Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.

- Pregnant or lactating female.

- Female planning to become pregnant or planning to discontinue contraceptive precautions in the 10 months post-transplantation.

- History of allergy to any component of the vaccine

- Patients with VZV disease after transplantation and prior to vaccination.

- Ongoing requirement for antiviral therapy with anti-VZV activity beyond 4 months post-transplantation

- Patients with difficult to treat disease who are likely to relapse within 6 months post-transplantation.

- Current drug and/or alcohol abuse.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
VarilrixTM
Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.

Locations

Country Name City State
Australia GSK Investigational Site East Melbourne Victoria
Australia GSK Investigational Site Melbourne Victoria
Australia GSK Investigational Site Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With a Varicella Vaccine Response Vaccine response was defined as: for initially seropositive subjects, an antibody titer at Month 8 post-transplantation above or equal to (=) 4 fold the pre-vaccination antibody titer. At 8 months post-transplantation = 1.5 months post-second dose of vaccination
Primary Anti-varicella Zoster Virus (Anti-VZV) Antibody Titers Antibody titers were measured by Indirect Immunofluorescence Assay (IFA) and presented as geometric mean titers (GMTs). At 8 months post-transplantation = 1.5 months post-second dose of vaccination
Secondary Number of Subjects With a Varicella Vaccine Response Vaccine response was defined as: for initially seropositive subjects, antibody titer at 6.5 months post-transplantation = 4 fold the pre-vaccination antibody titer. At 6.5 months post-transplantation = 2 months post first dose of vaccination
Secondary Number of Seropositive Subjects for Anti-varicella Antibodies The seropositivity cut-off titer of the assay was an anti-VZV antibody titer greater than or equal to (=) 1:4. At pre-transplantation (Month 0), pre-vaccination visit (at 4.5 months post-transplantation), Month 12 and Month 24 (5.5 and 17.5 months post-second dose of vaccination)
Secondary Anti-varicella Antibody Titers Antibody titers were were measured by Indirect Immunofluorescence Assay (IFA) and presented as geometric mean titers (GMTs). At pre-transplantation (Month 0), pre-vaccination visit (4.5 months post-transplantation), Month 12 and Month 24 (5.5 and 17.5 post-second dose of vaccination)
Secondary Number of Subjects With Any and Grade 3 Solicited Local Adverse Events Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site. During the 8-day (Days 0-7) post-vaccination period after each dose and across doses
Secondary Number of Subjects With Any Fever Any = fever equal to or greater than (=) 37.5 °C. Grade 3 fever = fever above (>) 39.0 °C. Related = fever assessed by the investigator as related to the vaccination. During the 43-day (Days 0-42) post-vaccination period after each dose and across doses
Secondary Number of Subjects With Any and Related Rash Rash was assessed as being either associated to the administration site or not. Non administration site rash was presented by following characteristics (with fever, measles/rubella like, varicella like and related). During the 43-day (Days 0-42) post-vaccination period after each dose and across doses
Secondary Number of Subjects With Any Unsolicited Adverse Events (AEs) An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period after each dose and across doses
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. During the active phase of the study (up to Month 24)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05015686 - Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00226499 - Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Not yet recruiting NCT06068608 - A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy Phase 1
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT00715234 - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients N/A
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT03239873 - Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT01390857 - Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) N/A
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00578175 - Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Phase 2
Completed NCT00568334 - Study of Two Formulations of GSK Biologicals' Varicella Vaccine Phase 2
Completed NCT03114982 - The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age Phase 2
Completed NCT00483574 - Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Phase 3
Completed NCT00127023 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3